Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
Sanofi's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $104.3B | |
|---|---|---|
| Revenue (ttm) | 55.9B | |
| Net income (ttm) | 4.5B | |
| EPS (ttm) | $1.82 | |
| Shares out | 1.2B | |
| P/E (trailing) | 23.2x | |
| P/E (forward) | 8.4x | |
| Dividend | $2.42 (5.73%) | |
| Volume | 2,730,232 | |
| Beta | 0.28 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $40.56B | $41.62B | $44.29B | $46.72B | +4.8% |
| Gross profit | $28.68B | $28.99B | $31.08B | $33.67B | +5.5% |
| Operating income | $10.40B | $6.89B | $7.40B | $6.80B | -13.2% |
| Net income | $8.37B | $5.40B | $5.56B | $7.81B | -2.3% |
| EPS (diluted) | $2.69 | $2.16 | $2.30 | $3.20 | +6.0% |
| EBITDA | $13.51B | $11.32B | $10.99B | $12.48B | -2.6% |
| R&D | $6.50B | $6.51B | $7.39B | $7.84B | +6.5% |
| SG&A | $8.74B | $9.48B | $9.82B | $10.24B | +5.4% |
Recent company headlines from major financial publishers.
Revenue accelerates beyond the historical 4.82% CAGR toward the 6.12% next-year estimate, driven by successful pipeline commercialization. Operating margins improve past 20%, and the equity partially re-rates toward the peer median.
Growth remains stable, anchored by vaccines and rare diseases. The 12.0x terminal multiple reflects a conservative partial re-rating from the current 8.4x, deliberately constrained below peers due to the rigid 97.7% dividend payout policy.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 6.3% | $61.9 | $69.2 | $78.4 | $89.5 | $89.5 |
| 7.3% | $51.2 | $56.0 | $61.9 | $69.2 | $78.4 |
| 8.3% | $43.6 | $47.1 | $51.2 | $56.0 | $61.9 |
| 9.3% | $38.0 | $40.6 | $43.6 | $47.1 | $51.2 |
| 10.3% | $33.6 | $35.7 | $38.0 | $40.6 | $43.6 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
